Cramer's Mad Money - The Unsinkable Biogen IDEC (1/8/13)
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday January 8.
CEO Interview: George Sangos, Biogen IDEC (BIIB)
A recent clinical trial that ended in disappointment didn't bring Biogen IDEC (BIIB) down; the stock barely budged after the lackluster data were released. One reason BIIB's shares held firm is that Biogen has many other things going its way, including 2 major drugs for Multiple Sclerosis and one additional drug on the way that can be administered orally and not through injection. When Cramer asked CEO George Sangos if this new MS drug could take market share away from BIIB's other drugs, Sangos explained that there is enough diversification among patients and physicians in attitudes and needs during treatment that there will be sufficient demand for all three drugs. Currently, BIIB has 30% market share in the MS treatment market. BIIB is developing what is hoped to be the top drug to treat hemophilia, and will entail fewer injections for hemophilia sufferers than are required under current treatment programs. READ FULL ARTICLE HERE
Citybizlist Partner News
- Davis, Malm & D'Agostine - Davis Malm Shareholder Robert J. Galvin Quoted in Noted Condominium Resource Hoaleader.com
- Pierce Atwood - Bruce Miller to Present at "Not Just Another SBA Seminar"
- Davis, Malm & D'Agostine - Tamsin R. Kaplan Presents to the Woman to Woman Group at New Directions, Inc.
- Pierce Atwood - Cliff Ruprecht & Gavin McCarthy Present at MSBA Litigation Institute